Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.vaccine.2020.07.013

http://scihub22266oqcxt.onion/10.1016/j.vaccine.2020.07.013
suck pdf from google scholar
32684499!7351416!32684499
unlimited free pdf from europmc32684499    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32684499      Vaccine 2020 ; 38 (40): 6194-6198
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Planning for COVID-19 vaccines safety surveillance #MMPMID32684499
  • Kochhar S; Salmon DA
  • Vaccine 2020[Sep]; 38 (40): 6194-6198 PMID32684499show ga
  • COVID-19 vaccines are the most important tool to stem the pandemic. They are being developed with unprecedented global collaboration and accelerated timelines to achieve WHO Emergency Use Listing, while using regulatory pathways through national regulatory authorities. Alongside preparations to ensure equitable access to the vaccines among people globally, preparations must be made within countries for COVID-19 vaccines safety surveillance on an urgent basis. Safety surveillance must be capable of investigating adverse events of special interest (AESI) and adverse events following immunization to determine a change in the benefit-risk profile of the vaccine, and to be able to anticipate coincidental events that might be attributed to the vaccine. Active surveillance systems should calculate the incidence of background rates of AESI prior to vaccine roll out. These background rates vary tremendously across regions, populations and case ascertainment methods. Active surveillance systems must be established or strengthened now, (including in LMIC), to calculate the background rates. Utilizing standardized case definitions and global standards for AESI will help in harmonization. Vaccine safety communication plans should be developed. Expanding the global vaccine safety system to meet the needs of COVID-19 and other emergency and routine use vaccines is a priority currently.
  • |Adverse Drug Reaction Reporting Systems[MESH]
  • |Betacoronavirus/*immunology[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Vaccines[MESH]
  • |Coronavirus Infections/*immunology/*prevention & control[MESH]
  • |Humans[MESH]
  • |Pandemics/*prevention & control[MESH]
  • |Pneumonia, Viral/*immunology/*prevention & control[MESH]
  • |Product Surveillance, Postmarketing[MESH]
  • |SARS-CoV-2[MESH]
  • |Vaccination[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box